Finally, we investigated combinations of the dual HDAC6/LSD1 inhibitor with cytotoxic agents that are the current standard of care in acute myeloid leukemia (AML) and discovered a significant enhancement of doxorubicin sensitivity. The gene discussed is HDAC6; the disease is acute myeloid leukemia.